627 related articles for article (PubMed ID: 27926518)
1. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
[TBL] [Abstract][Full Text] [Related]
2. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
[TBL] [Abstract][Full Text] [Related]
3. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
4. Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Eckel-Passow JE; Ho TH; Serie DJ; Cheville JC; Houston Thompson R; Costello BA; Dong H; Kwon ED; Leibovich BC; Parker AS
Cancer Med; 2020 Feb; 9(3):1152-1160. PubMed ID: 31829518
[TBL] [Abstract][Full Text] [Related]
5. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
6. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.
Kammerer-Jacquet SF; Brunot A; Lefort M; Bayat S; Peyronnet B; Verhoest G; Mathieu R; Lespagnol A; Mosser J; Laguerre B; Ravaud A; Bernhard JC; Dupuis F; Yacoub M; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
Clin Genitourin Cancer; 2019 Jun; 17(3):169-176.e1. PubMed ID: 30837208
[TBL] [Abstract][Full Text] [Related]
12. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
[TBL] [Abstract][Full Text] [Related]
13. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Ascierto ML; McMiller TL; Berger AE; Danilova L; Anders RA; Netto GJ; Xu H; Pritchard TS; Fan J; Cheadle C; Cope L; Drake CG; Pardoll DM; Taube JM; Topalian SL
Cancer Immunol Res; 2016 Sep; 4(9):726-33. PubMed ID: 27491898
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression.
Wang J; Xi J; Zhang H; Li J; Xia Y; Xi R; Xi Z
Cancer Commun (Lond); 2019 Jun; 39(1):37. PubMed ID: 31227023
[No Abstract] [Full Text] [Related]
15. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.
Choueiri TK; Figueroa DJ; Fay AP; Signoretti S; Liu Y; Gagnon R; Deen K; Carpenter C; Benson P; Ho TH; Pandite L; de Souza P; Powles T; Motzer RJ
Clin Cancer Res; 2015 Mar; 21(5):1071-7. PubMed ID: 25538263
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Tatli Dogan H; Kiran M; Bilgin B; Kiliçarslan A; Sendur MAN; Yalçin B; Ardiçoglu A; Atmaca AF; Gumuskaya B
Diagn Pathol; 2018 Aug; 13(1):60. PubMed ID: 30144808
[TBL] [Abstract][Full Text] [Related]
17. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Zhu X; Zhao P; Zhao J; Liu J; Chen N; Wang J; Shen P; Zeng H
BMC Cancer; 2019 Apr; 19(1):360. PubMed ID: 30992011
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
[No Abstract] [Full Text] [Related]
20. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]